<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739242</url>
  </required_header>
  <id_info>
    <org_study_id>MEIF/MOF-Col/001</org_study_id>
    <nct_id>NCT03739242</nct_id>
  </id_info>
  <brief_title>Effect of a Treatment With a Nutraceutical Combination on Sub-optimal LDL Cholesterol Levels</brief_title>
  <acronym>NATCOL</acronym>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Clinical Study of the Effects of a Nutraceutical Combination on LDL Cholesterol Levels in Subjects With Sub-optimal Blood Cholesterol Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A. Menarini Industrie Farmaceutiche Riunite S.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A. Menarini Industrie Farmaceutiche Riunite S.r.l.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High cholesterol is one of the major controllable risk factor for coronary heart disease. It
      is well demonstrated that drugs that reduce the intestinal absorption of cholesterol or block
      the synthesis of cholesterol or the association of both, can reduce cholesterol and reduce
      rate of cardiovascular events. The trial will evaluate natural alternative to this drug
      approach testing the effects of a combination of phytosterol, a nutritional that reduce
      cholesterol absorption, and fermented red rice, a nutritional that reduce the synthesis of
      cholesterol. Subjects with sub optimal blood cholesterol levels, matching all the inclusion
      criteria and none of the exclusion criteria, will be treated for 8 weeks with a nutraceutical
      combination of phytosterols and fermented red rice and will have to maintain, during the
      entire duration of the study, the Mediterranean-style diet provided. The study will evaluate
      as primary objective the changes in LDL cholesterol blood levels and more in general the
      modulation of lipid profile and of others clinical parameters as well as the tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is made up of four visits distributed over a 10-weeks period:

      V 1 (day -14) - Screening: After providing written informed consent, tests will be run in
      order to check the subject's eligibility for the study. Subjects will also be given
      suggestions regarding their diet (a Mediterranean-style diet is to be maintained for the
      entire duration of the study).

      V2 (baseline) and Day 0 (randomization): After confirmation of the subject's eligibility
      [LDL-C and Triglycerides (TG) criteria confirmed with blood test results], eligible subjects
      will be randomized within 3 days to one of the two treatment groups. During this visit an
      endothelial reactivity test will be performed.

      V3 (28 ±3 days after Day 0) - Intermediate: Blood will be drawn for tests and compliance with
      treatment will be assessed. V4 (28 ± 3 days after Visit 3) - End of study: Blood tests and an
      endothelial reactivity test will be performed and treatment compliance will be assessed.

      Weight, waist circumference, Index of Central Obesity (ICO) and Body Mass Index (BMI),
      Hepatic Steatosis Index (HSI) and Lipid Accumulation Product (LAP) will be
      measured/calculated at each visit, height at Visit 1.

      Heart rate and blood pressure will be measured at each visit. Adverse events (AEs) will be
      collected throughout the study starting from the Informed consent signature.

      The study will be monitored according to the details specified in the Monitoring Plan. The
      monitor will have the responsibility of reviewing the ongoing study with the Investigator to
      verify adherence to the protocol and to deal with any problems. Case Report Form (CRF) will
      be checked for completeness and consistency with the source data and special attention will
      be dedicated to patient enrolment, obtaining signed informed consent, occurrence of AEs,
      product accountability, and accurate recording of variables. The confidentiality of study
      related documents shall be maintained at all times. The Investigator agrees to allow access
      to all study materials needed for the proper review of study conduct.

      An independent quality audit/inspection at the study site may take place at any time during
      or after the study. The independent audit/inspection can be carried out by the Sponsor's
      independent Quality Assurance (QA), by a Health Authorities or an Ethics Committee (EC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Actual">August 29, 2018</completion_date>
  <primary_completion_date type="Actual">August 29, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood LDL Cholesterol Level</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in blood LDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Blood Cholesterol Level</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in total blood LDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood HDL Cholesterol Level</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in blood HDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Non-HDL Cholesterol Level</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in blood non-HDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Triglycerides Level</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in blood triglycerides level from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Apolipoprotein B Level</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in blood apolipoprotein B level from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol/HDL Cholesterol Ratio</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in total cholesterol/HDL cholesterol ratio from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total LDL Cholesterol/HDL Cholesterol Ratio</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in LDL/HDL cholesterol ratio from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse Volume (PV) Waveform (Endothelial Reactivity)</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in Pulse Volume (PV) waveform from randomization (day 0) to V4 (week 8).
PV unit of measurement is a percent change in the PV waveform area, comparing waveforms during and before hyperemia through the equation √PV2/PV1 that relates PV at baseline (PV1) and PV during hyperemia (PV2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycemia</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in Glycemia from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aspartate Aminotransferase (AST)</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in aspartate aminotransferase from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT)</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in aspartate aminotransferase from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gamma Glutamyl Transpeptidase (GGT)</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change gamma glutamyl transpeptidase (GGT) from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in Serum Creatinine values from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Uric Acid</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in Serum uric acid values from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Creatine Phosphokinase (CPK)</measure>
    <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
    <description>Mean change in creatine phosphokinase (CPK) from randomization (day 0) to V4 (week 8)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Nutraceutical combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutraceutical combination</intervention_name>
    <description>One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
    <arm_group_label>Nutraceutical combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        Subjects must meet all of the following inclusion criteria:

          -  Age 30-75 years

          -  LDL-cholesterol = 115 -190 mg/dL

          -  Triglycerides &lt; 400 mg/dL

          -  Any cardiovascular therapy should be stable for type and dose for at least three
             months

          -  Signed, written informed consent

        Exclusion Criteria:

        -

        Subjects must meet none of the following exclusion criteria:

          -  Intolerance to any ingredient of dietary supplement

          -  Patients already suffering from cardiovascular diseases or at high risk of developing
             cardiovascular diseases

          -  Myopathies

          -  Uncontrolled diabetes mellitus based on PI judgment

          -  Chronic renal failure [defined as estimated glomerular filtration rate (eGFR)
             &lt;60ml/min/1.73m2] or liver failure [defined as aspartate aminotransferase (AST) and
             /or Alanine Aminotransferase (ALT) &gt;3 upper limit of normal (ULN)]

          -  Body Mass Index &gt; 32 kg/m2

          -  Therapy with statins or other drugs or supplements with effects on lipid metabolism

          -  Patients with acquired immunodeficiency

          -  Treatment with immunosuppressants

          -  Pregnant or breastfeeding women

          -  Women of childbearing potential not willing to use effective birth control methods

          -  Patients participating or having participated in another clinical trial within the
             previous 3 months

          -  Current or recent history of drug or alcohol addiction based on PI judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Borghi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico S.Orsola - Malpighi Medicina Interna Borghi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico S.Orsola - Malpighi Medicina Interna Borghi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <results_first_submitted>September 3, 2019</results_first_submitted>
  <results_first_submitted_qc>October 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2019</results_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipids</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Low density lipoprotein cholesterol</keyword>
  <keyword>Dietary Fats</keyword>
  <keyword>Hyperlipidemias</keyword>
  <keyword>Dietary Supplements</keyword>
  <keyword>Food Supplements</keyword>
  <keyword>Nutraceuticals</keyword>
  <keyword>Nutriceuticals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03739242/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03739242/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nutraceutical Combination</title>
          <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
      <group_list>
        <group group_id="B1">
          <title>Nutraceutical Combination</title>
          <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.28" spread="9.56"/>
                    <measurement group_id="B2" value="51.79" spread="10.74"/>
                    <measurement group_id="B3" value="51.53" spread="10.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL blood cholesterol level</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154.27" spread="20.47"/>
                    <measurement group_id="B2" value="160.57" spread="20.84"/>
                    <measurement group_id="B3" value="157.38" spread="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Blood LDL Cholesterol Level</title>
        <description>Mean change in blood LDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood LDL Cholesterol Level</title>
          <description>Mean change in blood LDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.48" spread="30.18"/>
                    <measurement group_id="O2" value="2.54" spread="19.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-39.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.57</ci_lower_limit>
            <ci_upper_limit>-29.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Blood Cholesterol Level</title>
        <description>Mean change in total blood LDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Blood Cholesterol Level</title>
          <description>Mean change in total blood LDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.99" spread="34.05"/>
                    <measurement group_id="O2" value="7.17" spread="21.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-41.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.73</ci_lower_limit>
            <ci_upper_limit>-30.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood HDL Cholesterol Level</title>
        <description>Mean change in blood HDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood HDL Cholesterol Level</title>
          <description>Mean change in blood HDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="7.17"/>
                    <measurement group_id="O2" value="1.11" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9510</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.87</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Non-HDL Cholesterol Level</title>
        <description>Mean change in blood non-HDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Non-HDL Cholesterol Level</title>
          <description>Mean change in blood non-HDL cholesterol level from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.35" spread="22.99"/>
                    <measurement group_id="O2" value="3.65" spread="18.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-41.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.58</ci_lower_limit>
            <ci_upper_limit>-31.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Triglycerides Level</title>
        <description>Mean change in blood triglycerides level from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Triglycerides Level</title>
          <description>Mean change in blood triglycerides level from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="42.76"/>
                    <measurement group_id="O2" value="17.62" spread="60.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1924</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-7.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.59</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Apolipoprotein B Level</title>
        <description>Mean change in blood apolipoprotein B level from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Apolipoprotein B Level</title>
          <description>Mean change in blood apolipoprotein B level from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.79" spread="15.05"/>
                    <measurement group_id="O2" value="1.6" spread="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-17.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.54</ci_lower_limit>
            <ci_upper_limit>-10.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol/HDL Cholesterol Ratio</title>
        <description>Mean change in total cholesterol/HDL cholesterol ratio from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol/HDL Cholesterol Ratio</title>
          <description>Mean change in total cholesterol/HDL cholesterol ratio from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.79"/>
                    <measurement group_id="O2" value="0.06" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>-0.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total LDL Cholesterol/HDL Cholesterol Ratio</title>
        <description>Mean change in LDL/HDL cholesterol ratio from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total LDL Cholesterol/HDL Cholesterol Ratio</title>
          <description>Mean change in LDL/HDL cholesterol ratio from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.70"/>
                    <measurement group_id="O2" value="-0.01" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulse Volume (PV) Waveform (Endothelial Reactivity)</title>
        <description>Mean change in Pulse Volume (PV) waveform from randomization (day 0) to V4 (week 8).
PV unit of measurement is a percent change in the PV waveform area, comparing waveforms during and before hyperemia through the equation √PV2/PV1 that relates PV at baseline (PV1) and PV during hyperemia (PV2).</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse Volume (PV) Waveform (Endothelial Reactivity)</title>
          <description>Mean change in Pulse Volume (PV) waveform from randomization (day 0) to V4 (week 8).
PV unit of measurement is a percent change in the PV waveform area, comparing waveforms during and before hyperemia through the equation √PV2/PV1 that relates PV at baseline (PV1) and PV during hyperemia (PV2).</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.25"/>
                    <measurement group_id="O2" value="-0.03" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4535</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-3.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.64</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycemia</title>
        <description>Mean change in Glycemia from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycemia</title>
          <description>Mean change in Glycemia from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="6.26"/>
                    <measurement group_id="O2" value="-1.57" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5594</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.76</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Aspartate Aminotransferase (AST)</title>
        <description>Mean change in aspartate aminotransferase from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aspartate Aminotransferase (AST)</title>
          <description>Mean change in aspartate aminotransferase from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="4.01"/>
                    <measurement group_id="O2" value="0.86" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9266</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.63</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alanine Aminotransferase (ALT)</title>
        <description>Mean change in aspartate aminotransferase from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alanine Aminotransferase (ALT)</title>
          <description>Mean change in aspartate aminotransferase from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" spread="9.29"/>
                    <measurement group_id="O2" value="2.93" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2654</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>6.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.66</ci_lower_limit>
            <ci_upper_limit>16.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gamma Glutamyl Transpeptidase (GGT)</title>
        <description>Mean change gamma glutamyl transpeptidase (GGT) from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gamma Glutamyl Transpeptidase (GGT)</title>
          <description>Mean change gamma glutamyl transpeptidase (GGT) from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="9.83"/>
                    <measurement group_id="O2" value="3.07" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2595</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-5.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.37</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <description>Mean change in Serum Creatinine values from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <description>Mean change in Serum Creatinine values from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.08"/>
                    <measurement group_id="O2" value="0" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8476</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>0.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.032</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Uric Acid</title>
        <description>Mean change in Serum uric acid values from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Uric Acid</title>
          <description>Mean change in Serum uric acid values from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.98"/>
                    <measurement group_id="O2" value="0" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1499</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Creatine Phosphokinase (CPK)</title>
        <description>Mean change in creatine phosphokinase (CPK) from randomization (day 0) to V4 (week 8)</description>
        <time_frame>From randomization (day 0) to V4 (week 8) for a total of 56 +/- 3 days of treatment</time_frame>
        <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Combination</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatine Phosphokinase (CPK)</title>
          <description>Mean change in creatine phosphokinase (CPK) from randomization (day 0) to V4 (week 8)</description>
          <population>Population analysed is the Full Analysis Set one (FAS), composed by all randomization subjects who completed all the visits and were assessed for LDL cholesterol at last visit (Visit 4 - Week 8).</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="48.76"/>
                    <measurement group_id="O2" value="-7.00" spread="56.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7224</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean difference</param_type>
            <param_value>1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.83</ci_lower_limit>
            <ci_upper_limit>11.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) were collected from signature of the Informed Consent at screening visit, to the last visit (Visit 4) occurred 56 +/- 3 days after. Total period of AE collection throughout the study was of eleven months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nutraceutical Combination</title>
          <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
Nutraceutical combination: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
Placebo: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations or caveats are applicable to this summary</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Paolo Fabrizzi Clinical Operation Director</name_or_title>
      <organization>A. Menarini Industrie Farmaceutiche Riunite SrL</organization>
      <phone>+39 055 5680459</phone>
      <email>pfabrizzi@menarini.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

